Keuangan UnitedHealth Group Incorporated (UNH)
NYSE · Healthcare · Medical - Healthcare Plans · Karyawan: 390.000 · CEO: Stephen J. Hemsley
- Harga
- $406,97 -0,96%
- Kapitalisasi pasar
- $365 M
- Nilai perusahaan
- $414 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-13
- Laporan berikutnya
- 2027-01-20 Estimasi EPS: $2,28
Valuasi & angka utama
- Kapitalisasi pasar
- $365 M EV $414 M
- Pendapatan
- $450 M 12 bulan terakhir
- Pertumbuhan pendapatan
- 0% Konsensus FY2026
- Margin laba
- 3,5% Laba bersih / pendapatan, TTM
- P/E
- 23,2× Forward 19,8× (FY2026)
- P/S
- 0,8× Harga / penjualan, TTM
- EV / EBITDA
- 14,8× TTM
- Arus kas bebas
- $22,8 M 12 bulan terakhir
- Laba bersih
- $15,9 M 12 bulan terakhir
- Estimasi pendapatan
- $448 M Konsensus FY2026
- Laba
- 2027-01-20 Estimasi pendapatan: $112 M
- Dividen
- $9,06 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-13): pendapatan melampaui 1,2%, EPS melampaui 13,3%Pendapatan $113 M vs $111 M yang diharapkan (+1,2%); EPS $4,69 vs $4,14 (+13,3%).
- Pertumbuhan pendapatan melambat: -0,4% yoyPendapatan Q3 '26: $113 M, rata-rata empat kuartal sebelumnya: 6,7%.
- Margin operasional 5,3% (TTM), dibanding tahun lalu: -0,7 poinLaba operasional tumbuh -9,2%, pendapatan tumbuh 3,3%.
- 21,2% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $19,7 M vs laba operasional $23,9 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 0,7% dari pendapatan (tahun lalu 0,8%)$3,37 M diinvestasikan dalam 4 kuartal terakhir (-6,1% dibanding tahun sebelumnya). Arus kas bebas: $22,8 M = 143,7% dari laba bersih.
- $17,9 M dikembalikan ke pemegang saham = 78,6% dari arus kas bebasBuyback: $9,77 M (tahun lalu $5,78 M), dividen: $8,17 M, kompensasi saham: $1,02 M (TTM).
- Jumlah saham dilusian turun dalam setahun: 1,1%Saham dilusian pada Q3 '26: 902 jt, setahun sebelumnya: 912 jt.
- Utang neto: $45,8 MKas + investasi jangka pendek: $28,5 M, utang termasuk sewa: $74,3 M; tahun lalu utang neto: $49,5 M.
- Total Optum: pendapatan -2,3%, margin 6,2% (sebelumnya 4,6%)Segmen pelaporan dengan pertumbuhan tercepat pada Q2 '26: laba operasional $4,05 M dari pendapatan $65,7 M (dari catatan segmen dalam laporan).
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $113 M | $113 M | -0,4% |
| Margin kotor | 19,5% | 18,2% | +1,3 poin |
| Laba operasional | $6,56 M | $4,32 M | +52,1% |
| Margin operasional | 5,8% | 3,8% | +2,0 poin |
| Laba bersih | $4,11 M | $2,35 M | +75,0% |
| EPS dilusian | $4,56 | $2,59 | +76,1% |
| Arus kas operasional | $5,12 M | $5,95 M | -13,8% |
| Capex | $859 jt | $890 jt | -3,5% |
| Arus kas bebas | $4,26 M | $5,06 M | -15,6% |
| R&D | $0 | $0 | – |
| Kompensasi berbasis saham | $219 jt | $223 jt | -1,8% |
Dilaporkan vs konsensus
2026-10-13| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $113 M | $111 M | +1,2% |
| EPS (basis konsensus) | $4,69 | $4,14 | +13,3% |
Dari laporan 2026-10-13 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Unitedhealthcare | – | – | – | – | – | |
| Premiums | $87 M | – | 77,6% | – | – | |
| UnitedHealthcare | – | – | – | – | – | |
| Intersegment Eliminations | – | – | – | – | – | |
| Optumrx | – | – | – | – | – | |
| Corporate and Eliminations | – | – | – | – | – | |
| Optum Rx | – | – | – | – | – | |
| Optumhealth | – | – | – | – | – | |
| Optum Health | – | – | – | – | – | |
| Products | $13,8 M | – | 12,3% | – | – | |
| Services | $10 M | – | 8,9% | – | – | |
| Optum Insight | – | – | – | – | – | |
| Optuminsight | – | – | – | – | – | |
| Investment and other income | $1,22 M | – | 1,1% | – | – | |
| Optum Eliminations | – | – | – | – | – |
Laba segmen
Laba operasional per segmen pelaporan, dibaca dari catatan segmen setiap 10-Q / 10-K (rincian laba yang tidak ada di sebagian besar data feed).
Segmen pada Q2 '26
| Segmen | Pendapatan | yoy | Laba operasional | yoy | Margin | Margin tahun lalu | Laba operasional TTM |
|---|---|---|---|---|---|---|---|
| Total Optum | $65,7 M | -2,3% | $4,05 M | +31,7% | 6,2% | 4,6% | $9,92 M |
| Unitedhealthcare | – | – | $3,94 M | +90,0% | – | – | $11,8 M |
| Optum Health | – | – | $1,19 M | +177,4% | – | – | – |
| Optum Insight | – | – | $1,37 M | +13,6% | – | – | – |
| Optum Rx | – | – | $1,49 M | +3,4% | – | – | – |
| Corporate (unallocated) | – | – | $0 | – | – | – | $0 |
Laba operasional per segmen
kuartalanMargin operasional segmen
kuartalanKuartal keempat dihitung: 10-K melaporkan setahun penuh, dikurangi tiga kuartal dari 10-Q.
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $26,2 M
- Capex
- -$3,37 M
- Buyback
- -$9,77 M
- Dividen
- -$8,17 M
- Akuisisi
- -$1,61 M
- Utang neto diterbitkan
- -$5,82 M
- Kompensasi berbasis saham
- $1,02 M
- Arus kas bebas
- $22,8 M
- Dikembalikan ke pemegang saham / FCF
- 78,6%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 23,2× | 26,3× | 22,4× – 32,3× |
| EV / EBITDA | 14,8× | 16,8× | 14,9× – 18,6× |
| EV / Penjualan | 0,9× | 1,4× | 0,8× – 1,7× |
| Harga / FCF | 16,0× | 21,2× | 18,7× – 23,8× |
| Harga / Nilai buku | 3,5× | 5,4× | 3,2× – 6,6× |
| Imbal hasil FCF | 6,2% | 4,8% | 4,2% – 5,4% |
| Imbal hasil modal yang diinvestasikan | 10,0% | 12,5% | 8,2% – 14,3% |
| Imbal hasil ekuitas | 16,1% | 20,7% | 12,8% – 25,9% |
Analis
Target konsensus $478,68 (+17,6%)
rentang $380,00 – $531,00 · peringkat Buy
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $448 M | +0,2% | $20,60 | +55,7% | 19,8× | 18 |
| FY2027 | $463 M | +3,3% | $23,42 | +13,7% | 17,4× | 18 |
| FY2028 | $488 M | +5,3% | $27,18 | +16,1% | 15,0× | 15 |
| FY2029 | $511 M | +4,7% | $31,31 | +15,2% | 13,0× | 9 |
| FY2030 | $543 M | +6,3% | $34,92 | +11,5% | 11,7× | 6 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 319 angka yang ditandai UnitedHealth Group Incorporated dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $39,7 M | $34,3 M | +15,8% | $38 M | $34,3 M | +10,8% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $21,6 M | $24,1 M | -10,6% | $23 M | $22,4 M | +2,9% |
| Accounts Receivable, Allowance for Credit Loss, Current | $1,21 M2025-12-31 | $985 jt | +22,6% | $1,21 M | $985 jt | +22,6% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $7,55 M2025-12-31 | $6,97 M | +8,2% | $7,55 M | $6,97 M | +8,2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$2,52 M | -$2,54 M | +0,6% | -$2,06 M | -$3,39 M | +39,1% |
| Additional Paid in Capital | $0 | – | – | $559 jt | $0 | – |
| Allowance for Doubtful Other Receivables, Current | $3,76 M2025-12-31 | $2,86 M | +31,4% | $3,76 M | $2,86 M | +31,4% |
| Amortization of Intangible Assets | – | – | – | $1,7 M | $1,7 M | 0,0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 12 jt | 13 jt | -7,7% | 12 jt | 6 jt | +100,0% |
| Assets | $310 M | $309 M | +0,4% | $310 M | $298 M | +3,8% |
| Assets, Current | $86,9 M | $93,7 M | -7,3% | $90,6 M | $85,8 M | +5,6% |
| Assets, Fair Value Disclosure | $81,9 M | $77,5 M | +5,6% | $75,6 M | $74,5 M | +1,5% |
| Buildings and Improvements, Gross | $4,09 M2025-12-31 | $4,22 M | -3,0% | $4,09 M | $4,22 M | -3,0% |
| Business Combination, Consideration Transferred | $100 jt2025-12-31 | – | – | $4,8 M | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets | $1,89 M2025-12-31 | – | – | $1,89 M | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $305 jt2025-12-31 | – | – | $305 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables | $811 jt2025-12-31 | – | – | $811 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | $536 jt2025-12-31 | – | – | $536 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other | $32 jt2025-12-31 | – | – | $32 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | $525 jt2025-12-31 | $10,6 M | -95,0% | $525 jt | $10,6 M | -95,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | $923 jt2025-12-31 | – | – | $923 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $965 jt2025-12-31 | – | – | $965 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other | $355 jt2025-12-31 | – | – | $355 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | $247 jt2025-12-31 | – | – | $247 jt | – | – |
| Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest | $4,84 M2025-12-31 | – | – | $4,84 M | – | – |
| Capitalized Computer Software, Accumulated Amortization | $3,83 M2025-12-31 | $3,33 M | +15,1% | $3,83 M | $3,33 M | +15,1% |
| Capitalized Computer Software, Amortization | – | – | – | $1,7 M | $1,4 M | +21,4% |
| Capitalized Computer Software, Gross | $9,85 M2025-12-31 | $8,98 M | +9,6% | $9,85 M | $8,98 M | +9,6% |
| Capitalized Computer Software, Net | $6,02 M2025-12-31 | $5,66 M | +6,4% | $6,02 M | $5,66 M | +6,4% |
| Cash and Cash Equivalents, at Carrying Value | $28,6 M | $28,6 M | 0,0% | $24,4 M | $25,3 M | -3,7% |
| Cash and Cash Equivalents, Fair Value Disclosure | $28,6 M | $28,6 M | 0,0% | $24,4 M | $25,3 M | -3,7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $28,6 M | $28,6 M | 0,0% | $24,4 M | $25,3 M | -3,7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $584 jt | -$2,12 M | +127,5% | -$947 jt | -$115 jt | -723,5% |
| CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations | $635 jt | -$2,19 M | +129,0% | -$592 jt | $104 jt | -669,2% |
| Common Stock, Dividends, Per Share, Cash Paid | $2,32 | $2,21 | +5,0% | $8,73 | $8,18 | +6,7% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 3 M | 3 M | 0,0% | 3 M | 3 M | 0,0% |
| Common Stock, Shares, Issued | 905 jt | 905 jt | 0,0% | 906 jt | 915 jt | -1,0% |
| Common Stock, Shares, Outstanding | 905 jt | 905 jt | 0,0% | 906 jt | 915 jt | -1,0% |
| Common Stock, Value, Issued | $9 jt | $9 jt | 0,0% | $9 jt | $9 jt | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $186 jt | $166 jt | +12,0% | $751 jt | $837 jt | -10,3% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $5,53 M | $3,78 M | +46,4% | $13,4 M | $18 M | -25,8% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $5,71 M | $3,94 M | +44,9% | $14,1 M | $18,9 M | -25,2% |
| Cost of Goods and Services Sold | $13,4 M | $13 M | +2,7% | $50,7 M | $46,7 M | +8,5% |
| Costs and Expenses | $104 M | $106 M | -2,3% | $429 M | $368 M | +16,5% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $1,66 M | $1,26 M | +32,4% |
| Current Income Tax Expense (Benefit) | – | – | – | $3,64 M | $5,13 M | -28,9% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $598 jt | $416 jt | +43,8% |
| Current Year Claims and Claims Adjustment Expense | $75,6 M | $78,6 M | -3,8% | $313 M | $265 M | +18,3% |
| Debt Instrument, Face Amount | – | – | – | $42,6 M2020-12-31 | $39,8 M | +6,9% |
| Debt Securities, Available-for-sale | $50,3 M | $46,6 M | +7,9% | $48,2 M | $46,9 M | +2,7% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $109 jt | $131 jt | -16,8% | $229 jt | $62 jt | +269,4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $1,89 M | $2,21 M | -14,2% | $1,63 M | $2,96 M | -45,1% |
| Debt Securities, Available-for-sale, Amortized Cost | $52,1 M | $48,7 M | +7,0% | $49,6 M | $49,8 M | -0,5% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | $7,92 M | $5,54 M | +43,0% | $6,95 M | $5,44 M | +27,7% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $12,8 M | $12 M | +6,8% | $12 M | $12,1 M | -1,2% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $14,2 M | $14,4 M | -1,5% | $13,8 M | $14,8 M | -7,2% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $2,96 M | $3,53 M | -16,2% | $3,86 M | $3,95 M | -2,4% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $7,69 M | $5,19 M | +48,2% | $6,74 M | $5,09 M | +32,5% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $12,4 M | $11,5 M | +8,0% | $11,7 M | $11,2 M | +4,1% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01